Our aim was to review the use of high-dimensional biology techniques, specifically transcriptomics, proteomics, and metabolomics, in amniotic fluid to elucidate the mechanisms behind preterm birth or assessment of fetal development. We performed a comprehensive MEDLINE literature search on the use of transcriptomic, proteomic, and metabolomic technologies for amniotic fluid analysis. All abstracts were reviewed for pertinence to preterm birth or fetal maturation in human subjects. Nineteen articles qualified for inclusion. Most articles described the discovery of biomarker candidates, but few larger, multicenter replication or validation studies have been done. We conclude that the use of high-dimensional systems biology techniques to analyze amniotic fluid has significant potential to elucidate the mechanisms of preterm birth and fetal maturation. However, further multicenter collaborative efforts are needed to replicate and validate candidate biomarkers before they can become useful tools for clinical practice. Ideally, amniotic fluid biomarkers should be translated to a noninvasive test performed in maternal serum or urine.
GreenNSDamusKSimpsonJLResearch agenda for preterm birth: recommendations from the March of Dimes. Am J Obstet Gynecol. 2005;193(3 pt 1):626–635.
2.
MehtaTTanikMAllisonD. Towards sound epistemological foundations of statistical methods for high-dimensional biology. Nat Genet. 2004;36(9):943–947.
3.
RomeroREspinozaJGotschFThe use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. BJOG. 2006;113(suppl 3):118–135.
4.
RomeroRKusanovicJPGotschFIsobaric labeling and tandem mass spectrometry: a novel approach for profiling and quantifying proteins differentially expressed in amniotic fluid in preterm labor with and without intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med. 2010;23(4):261–280.
5.
ChoolaniMNarasimhanKKollaVHahnS. Proteomic technologies for prenatal diagnostics: advances and challenges ahead. Expert Rev Proteomics. 2009;6(1):87–101.
6.
KamathBMarcotteMDeFrancoE.Neonatal morbidity after documented fetal lung maturity in late preterm and early term infants. Am J Obstet Gynecol. 2011;204(6):518.e1–e8.
7.
BatesERouseDMannMChapmanVCarloWTitaA. Neonatal outcomes after demonstrated fetal lung maturity before 39 weeks gestation. Obstet Gynecol. 2010;116(6):1288–1295.
8.
GraçaGDuarteIFBarrosASImpact of prenatal disorders on the metabolic profile of second trimester amniotic fluid: a nuclear magnetic resonance metabonomic study. J Proteome Res. 2010;9(11):6016–6024.
9.
ChoCKShanSJWinsorEJDiamandisEP. Proteomics analysis of human amniotic fluid. Mol Cell Proteomics. 2007;6(8):1406–1415.
10.
KolialexiATountaGMavrouATsangarisGT. Proteomic analysis of amniotic fluid for the diagnosis of fetal aneuploidies. Expert Rev Proteomics. 2011;8(2):175–185.
11.
ChoCKShanSJWinsorEJDiamandisEP. Proteomics analysis of human amniotic fluid. Mol Cell Proteomics. 2007;6(8):1406–1415.
12.
HuiLSlonimDKWickHCJohnsonKLBianchiDW. The amniotic fluid transcriptome: a source of novel information about human fetal development. Obstet Gynecol. 2012;119(1):111–118.
LarrabeePBJohnsonKLLaiCGlobal gene expression analysis of the living human fetus using cell-free messenger RNA in amniotic fluid. JAMA. 2005;293(7):836–842.
15.
MassinghamLJJohnsonKLBianchiDWProof of concept study to assess fetal gene expression in amniotic fluid by nanoarray PCR. J Mol Diagn. 2011;13(5):565–570.
16.
BuhimschiIChristnerRBuhimischiC.Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. BJOG. 2005;112(2):173–181.
17.
BuhimschiIAZhaoGRosenbergVAAbdel-RazeqSThungSBuhimschiCS. Multidimensional proteomics analysis of amniotic fluid to provide insight into the mechanisms of idiopathic preterm birth. PLoS One. 2008;3(4):e2049.
18.
BujoldERomeroRKusanovicJPProteomic profiling of amniotic fluid in preterm labor using two-dimensional liquid separation and mass spectrometry. J Matern Fetal Neonatal Med. 2008;21(10):697–713.
19.
GravettMGNovyMJRosenfeldRGDiagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA. 2004;292(4):462–469.
20.
QuelozPACrettazDThadikkaranLProteomic analyses of amniotic fluid: potential applications in health and diseases. J Chromatogr B: Analyt Technol Biomed Life Sci. 2007;850(1-2):336–342.
21.
RomeroREspinozaJRogersWTProteomic analysis of amniotic fluid to identify women with preterm labor and intra-amniotic inflammation/infection: the use of a novel computational method to analyze mass spectrometric profiling. J Matern Fetal Neonatal Med. 2008;21(6):367–388.
22.
RüetschiURosenAKarlssonGProteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J Proteome Res. 2005;4(6):2236–2242.
23.
TamborVKacerovskyMAndrysCAmniotic fluid cathelicidin in PPROM pregnancies: from proteomic discovery to assessing its potential in inflammatory complications diagnosis. PLoS One. 2012;7(7):e41164.
24.
VuadensFBenayCCrettazDIdentification of biologic markers of the premature rupture of fetal membranes: proteomic approach. Proteomics. 2003;3(8):1521–1525.
25.
BockJ. Metabolomic profiling of amniotic fluid by proton nuclear magnetic resonance spectroscopy: correlation wtih fetal maturation and other clinical variables. Clin Chem. 1994;40(1):56–61.
26.
CliftonMJoeBZektzerAFeasibility of magnetic resonance spectroscopy for evaluating fetal lung maturity. J Pediatr Surg. 2006;41(4):768–773.
27.
CohnBRJoeBNZhaoSQuantitative metabolic profiles of 2nd and 3rd trimester human amniotic fluid using (1)H HR-MAS spectroscopy. MAGMA. 2009;22(6):343–352.
28.
GraçaGGoodfellowBJBarrosASUPLC-MS metabolic profiling of second trimester amniotic fluid and maternal urine and comparison with NMR spectral profiling for the identification of pregnancy disorder biomarkers. Mol Biosyst. 2012;8(4):1243–1254.
29.
RomeroRMazaki-ToviSVaisbuchEMetabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J Matern Fetal Neonatal Med. 2010;23(12):1344–1359.
30.
KellerSRidingerJRuppAKJanssenJWAltevogtP. Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med. 2011;9:86.
31.
BianchiDWMaronJJohnsonK. Insights into fetal and neonatal development through analysis of cell-free RNA in body fluids. Early Hum Dev. 2010;86(11):747–752.
32.
MyersAJ. The age of the “ome”: genome, transcriptome and proteome data set collection and analysis. Brain Res Bull. 2012;88(4):294–301.
33.
HarrisonPWWrightAEMankJE. The evolution of gene expression and the transcriptome–phenotype relationship. Semin Cell Dev Biol. 2012;23(2):222–229.
34.
BuhimschiCRosenbergVDulayATMultidimensional system biology: genetic markers and proteomic biomarkers of adverse pregnancy outcome in preterm birth. Am J Perinatol. 2008;25(3):175–188.
35.
ChoCKDiamandisEP. Application of proteomics to prenatal screening and diagnosis for aneuploidies. Clin Chem Lab Med. 2011;49(1):33–41.
36.
HanXAslanianAYatesJI. Mass spectrometry for proteomics. Curr Opin Chem Biol. 2008;12(5):483–490.
37.
KolialexiAMavrouASpyrouGTsangarisG. Mass spectrometry-based proteomics in reproductive medicine. Mass Spectrom Rev. 2008;27(6):624–634.
38.
BuhimschiIA. Using SELDI-TOF mass spectrometry on amniotic fluid and for clinical proteomics and theranostics in disorders of pregnancy. Methods Mol Biol. 2012;818:171–197.
39.
ChoCSmithCDiamandisE. Amniotic fluid proteome analysis from Down syndrome pregnancies for biomarker discovery. J Proteome Res. 2010;9(7):3574–3582.
40.
BahtiyarMOCopelJAMahoneyMJBuhimischiIABuhimischiCS. Proteomics: a novel methodology to complement prenatal diagnosis of chromosomal abnormalities and inherited human diseases. Am J Perinatol. 2007;24(3):167–182.
41.
HittiJLapidusJLuX. Noninvasive diagnosis of intraamniotic infection: proteomic biomarkers in vaginal fluid. Am J Obstet Gynecol. 2010;203(1):32.e1–e8.
42.
BuhimischiCSBhandariVHamarBDProteomic profiling of the amniotic fluid to detect inflammation, infection and neonatal sepsi. PLoS Med. 2007;4(1):e18.
43.
WeinerCPLeeKYBuhimschiCSChristnerRBuhimschiIA. Proteomic biomarkers that predict the clinical success of rescue cerclage. Am J Obstet Gynecol. 2005;192(3):710–718.
44.
RomeroREspinozaJGoncalvesLFKusanovicJPFrielLHassanS. The role of inflammation and infection in preterm birth. Semin Reprod Med. 2007;25(1):21–39.
45.
BuhimschiCSBuhimschiIAAbdel-RazeqSProteomic biomarkers of intra-amniotic inflammation: relationship with funisitis and early-onset sepsis in the premature neonate. Pediatr Res. 2007;61(3):318–324.
46.
BuhimschiIAZambranoEPettkerCMUsing proteomic analysis of the human amniotic fluid to identify histologic chorioamnionitis. Obstet Gynecol. 2008;111(2 pt 1):403–412.
47.
ThadikkaranLCrettazDSiegenthalerMAThe role of proteomics in the assessment of premature rupture of fetal membranes. Clin Chim Acta. 2005;360(1-2):27–36.
48.
BuhimschiCSWeinerCPBuhimschiIA. Proteomics, part II: the emerging role of proteomics over genomics in spontaneous preterm labor/birth. Obstet Gynecol Surv. 2006;61(8):543–553.
49.
GraçaGDuarteIF, Barros AS, et al. (1)H NMR based metabonomics of human amniotic fluid for the metabolic characterization of fetus malformations. J Proteome Res. 2009;8(8):4144–4150.
50.
MocoSCollinoSRezziSMartinFP. Metabolomics perspectives in pediatrics research [published online January 11, 2013]. Pediatr Res. 2013.
51.
FanosVVan den AnkerJNotoAMussapMAtzoriL. Metabo-lomics in neonatology: fact or fiction?Semin Fetal Neonatal Med. 2013;18(1):3–12.
52.
HillMParizekAKanchevaRSteroid metabolome in plasma from the umbilical artery, umbilical vein, maternal cubital vein and in amniotic fluid in normal and preterm labor. J Steroid Biochem Mol Biol. 2010;121(3-5):594–610.
53.
MenonRAroraCPHobelCJFortunatoSJ. Corticotrophin-releasing hormone in lipopolysaccharide-stimulated term fetal membranes and amniotic fluid from term and preterm birth in African Americans and Caucasians. Reprod Sci. 2008;15(5):477–483.
54.
EsplinMSPeltierMRHamblinSMonocyte chemotactic protein-1 expression is increased in human gestational tissues during term and preterm labor. Placenta. 2005;26(8-9):661–671.
55.
CoboTPalacioMNavarro-SastreAPredictive value of combined amniotic fluid proteomic biomarkers and interleukin-6 in preterm labor with intact membranes. Am J Obstet Gynecol. 2009;200(5):499.e1–e6.
56.
BuhimschiCSDulayATAbdel-RazeqSFetal inflammatory response in women with proteomic biomarkers characteristic of intra-amniotic inflammation and preterm birth. BJOG. 2009;116(2):257–267.
57.
Conde-AgudeloAPapageorghiouATKennedySHVillarJ. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. BJOG. 2011;118(9):1042–1054.
58.
GoodpasterARomick-RosendaleLKennedyM. Statistical significance analysis of nuclear magnetic resonance-based metabonomics data. Anal Biochem. 2010;401(1):134–143.
59.
BuhimschiIABuhimschiCS. Proteomics/diagnosis of chorioamnionitis and of relationships with the fetal exposome. Semin Fetal Neonatal Med. 2012;17(1):36–45.
60.
EsplinMSMerrellKGoldenbergR. Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth. Am J Obstet Gynecol. 2011;204(5):391.e1–e8.
61.
BianchiDWPlattLDGoldbergJDAbuhamadAZSehnertAJRavaRP. Genome-wide fetal anueploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012;119(5):890–901.
